Vortioxetine Intravenous Infusion at Initiation of Oral Treatment With Vortioxetine in Patients With Depression
Status:
Completed
Trial end date:
2019-08-28
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of vortioxetine given as a
single intravenous dose of 25 mg at initiation of an oral vortioxetine regimen of 10 mg/day
for 7 days